BioTuesdays

Tag - Andrew Fein

Foghorn Therapeutics

HCW starts Foghorn Therapeutics at buy; PT $25

H.C. Wainwright initiated coverage of Foghorn Therapeutics (NASDAQ:FHTX) with a “buy” rating and price target of $25. The stock closed at $13.68 on Nov. 19. Foghorn is a leader in the field of chromatin biology. The...

Sutra-Biopharma-Logo

HCW starts Sutro Biopharma at buy; PT $35

H.C. Wainwright initiated coverage of Sutro Biopharma (NASDAQ:STRO) with a “buy” rating and price target of $35. The stock closed at $18.73 on June 17. “We believe Sutro Biopharma can continue to be a standout performer...

Unity-Biotechnology

HCW starts UNITY Biotechnology at buy; PT $12

H.C. Wainwright launched coverage of UNITY Biotechnology (NASDAQ:UBX) with a “buy” rating and $12 price target. The stock closed at $4.56 on June 4. UNITY is focusing on therapeutics addressing diseases of aging, while...

Prothena

HCW starts Prothena at buy; PT $22

H.C. Wainwright launched coverage of Prothena (NASDAQ:PRTA) with a “buy” rating and price target of $22. The stock closed at $11.53 on Dec 4. Prothena is focused on protein-opathies affecting the central nervous system...

Liquidia Logo

HCW starts Liquidia Technologies at buy; PT $6

H.C. Wainwright initiated coverage of Liquidia Technologies (NASDAQ:LQDA) with a “buy” rating and price target of $6. The stock closed at $2.92 on Dec. 3. Liquidia is focused on applying its particle engineering PRINT...

Syros-Logo

HCW ups Syros to buy; PT to $15 from $11

H.C. Wainwright upgraded Syros Pharmaceuticals (NASDAQ:SYRS) to “buy” from “neutral” and upped its price target to $15 from $11, saying the company “has turned a corner, in our opinion.” The stock closed at $6.67 on Nov...

Strongbridge Biopharma Logo

HCW cuts Strongbridge Biopharma PT to $10 from $18

H.C. Wainwright reduced its price target for Strongbridge Biopharma (NASDAQ:SBBP) to $10 from $18, citing an analysis of the changing dynamics of the Cushing’s syndrome landscape because of competitor programs. The...

Corbus Pharmaceuticals

HCW reduces Corbus Pharma PT to $6 from $24

H.C. Wainwright slashed the price target for Corbus Pharmaceuticals (NASDAQ:CRBP) to $6 from $24 but maintained its “buy” rating after the company’s Phase 3 RESOLVE-1 trial of lenabasum in cutaneous systemic sclerosis...

Aimmune Therapeutics

HCW halves Aimmune Therapeutics PT to $15 from $30

H.C. Wainwright halved its price target for Aimmune Therapeutics (NASDAQ:AIMT) to $30 from $15, and reiterated its “neutral” rating, citing the pandemic’s impact on the launch of Palforzia, the first drug treatment of...

Keros Therapeutics Logo

Analysts start Keros Therapeutics at buy, OP

Analysts for H.C. Wainwright and SVB Leerink launched coverage of Keros Therapeutics (NASDAQ:KROS) with “buy” and “outperform” ratings, respectively, citing Keros’ pipeline and platform differentiation. HCW analyst...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.